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Although  it has been clearly demonstrated that  antibodies  to pneumococcal cap- 
sules are protective in both mice and men (1, 2), the protective properties of antibodies 
to other pneumococcal constituents  have been less well investigated.  In the present 
report we describe results indicating that naturally occurring antibodies binding with 
the phosphocholine (PC)1 determinant of the pneumococcal cell wall C-carbohydrate 
(3)  are important in the protection of mice from experimental pneumococcal infec- 
tions. 
We made this observation while investigating what effects the immune deficiency 
of the CBA/N mouse might have on its susceptibility to pneumoeoccal infection. This 
strain  carries  an  X-linked  inability  (xid)  to  produce  normal  humoral  antibody 
responses  to  a  group  of thymus  independent  (TI-2),  predominantly  carbohydrate 
antigens  (4),  including  type  3  pneumococcal  capsular  polysaccharide  (5),  trinitro- 
phenyl-Fieoll  (6),  PC  (7,  8),  dextran  (9),  levan  (8),  and  group  A  streptococcal 
carbohydrate  (10).  The CBA/N  mouse  is  probably unable  to  make high  levels of 
anticarbohydrate antibodies in general because the bulk of mouse anticarbohydrate 
antibodies  is either IgM or IgGa (11),  and CBA/N mice produce low levels of IgM 
(12,  13)  and  virtually  no serum  IgGa (13),  In other respects, CBA/N  mice appear 
immunologically normal because they make relatively normal antibody responses to 
T-dependent antigens (14-16), they have relatively normal levels of the other murine 
immunoglobulin isotypes (13), and they express normal cell-mediated immunity (6). 
By infecting CBA/N mice with various pathogens, it should be possible to determine 
whether  anti-carbohydrate  antibodies  play important  roles  in  defense.  Our studies 
have clearly demonstrated  that  CBA/N mice are highly susceptible to intravenous 
infection with  type 3 pneumococci  (17),  but  contrary to our expectations, we have 
found  that  naturally  occurring  antibody  to  PC  rather  than  induced  anti-type  3 
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capsular  antibody was  important  for survival. Other investigators have shown  that 
CBA/N mice are also especially susceptible to Salmonella  typhimurium,  Ascaris suum, and 
Plasmodium yoelii (18-20). 
Materials and Methods 
Mice.  (CBA/N ×  DBA/2)F1 (C ×  D) males and (DBA/2 ×  CBA/N)F~ (D ×  C) males were 
obtained from the Rodent and Rabbit Production Unit of the National Institutes of Health, 
Bethesda,  Md.  BALB/cJ mice were  obtained  from  The Jackson  Laboratory,  Bar  Harbor, 
Maine. 
Bacterial Strains.  A human isolate of type 3 pneumococci was obtained courtesy of Mr. John 
Courtney, Washington University School of Medicine. This isolate had been maintained over 
a period of 15 yr by annual passage through mice. After three additional mouse passages,  strain 
WU1  was established from a smooth colony. From a  subsequent mouse passage of WU1, we 
isolated a more virulent subline, WU2. Two additional mouse passages  have not increased the 
virulence of WU2.  Both  sublines  were  shown  to  be  type  3  by  specific antisera.  Group  A 
streptococcus, J17A4 (21), was obtained from Dr. R. Lancefield, The Rockefeller University. S. 
typhimurium, SR-11 (22), was obtained from Dr. L. J. Berry, The University of Texas at Austin. 
Streptococcus pneumoniae, R36A (23), was obtained from Dr. A. Tomasz, The Rockefeller Univer- 
sity. Listeria monocytogenes, LM-22, was obtained from Dr. D. M¢/Gregor, Cornell University. All 
cultures were stored at -70°C in media (see below), except for S. pneumoniae which was frozen 
in  medium  plus  10%  glycerol. Freshly thawed  euhures  of L.  monocytogenes and  S.  typhimurium 
were grown in Todd-Hewitt broth (Difco Laboratories, Detroit, Mich.) supplemented with 5% 
yeast extract (Difco Laboratories). Streptococcal and pneumococcal cultures were grown in the 
same medium supplemented with 0.2% heparinized human blood. Pneumococci for infection 
were grown from a frozen stock as indicated above for ~6-8 h and harvested by centrifugation 
at  4°C while still in  log phase.  The bacteria were washed  once and  suspended  in  Ringers- 
lactate solution. Optical density (OD) at 420 nm was determined (OD of 1 --- 3 ×  10  a cocci/ 
ml). The bacteria were kept at 4°C from the time of harvest until injection. Immediately after 
injection, the inoculum was plated on blood agar to determine the number of colony-forming 
units per milliliter, and to examine colony morphology. 
Protection of C ×  D Males with Normal Mouse Serum (NMS).  Pools of NMS were obtained by 
bleeding about 40 8-12-wk-old C X D and D X C males. Harvested NMS was heat inactivated 
at 56°C for 40 min, filter sterilized, and stored at -20°C. About 200 live bacteria were added 
per 0.1  mi of NMS.  After 30  min  incubation  on  ice,  an  equal  volume of cold Ringers was 
added,  and  mice were  injected  intravenously with  0.2  ml  of the  mixture.  Injections  were 
planned so that each cage contained about equal numbers of mice receiving D  ×  C and C  × 
D NMS. 
Levels of Anti-PC Antibody m  NMS.  These values were determined by radioimmunoassay. 
The wells of vinyl microtiter plates (Cooke-Dynatech Laboratories, Inc., Alexandria, Va.) were 
coated overnight with 0.1  ml of PC-bovine serum albumin  (BSA) at  10 ~g/ml in phosphate- 
buffered saline (PBS).  The PC-BSA was prepared as described elsewhere (24). The wells were 
rinsed, filled with  1% (BSA) in 0.005  M  PBS, pH 7.4 (1% BSA-PBS), and allowed to stand for 
3 h at room temperature. A  1:30 dilution of normal serum in  1% BSA-PBS was added to the 
first well and diluted out in subsequent wells with threefold serial dilutions. Plates were allowed 
to stand overnight at 4°C, and rinsed with PBS. Wells were then filled with 0.1 ml of 1% BSA- 
PBS containing 50,000 epm of 125I-labeled goat anti-mouse x antibody (25). After an additional 
overnight incubation at 4°C, the wells were rinsed, cut from plates, and counted in a gamma 
counter. Maximum counts bound to the wells was ~30,000.  For each serum we determined the 
dilution  binding  15,000 epm  of  the  label.  Anti-PC  titers  could  be  inhibited  with  0.1% 
phosphocholine chloride. By comparing the titers of the normal sera with the titers of samples 
containing known amounts of hybridoma antibody, we calculated the amount of antibody in 
the NMS. 
Absorption of NMS with Bacteria and Immunoabsorbents.  Bacteria were grown in starter cultures 
as described above and then grown in 500 ml vol of Todd-Hewitt broth plus 0.5% yeast extract 
for 6-12 h. While the cultures were still in log phase, they were killed with formaldehyde (0.2% 696  ANTIPHOSPHOCHOLINE  ANTIBODIES IN NORMAL  MOUSE  SERUM 
final concentration, 12-24 h  at  room temperature)  (26). Killed bacteria were harvested by 
centrifugation, washed twice with Ringers solution, once with 1% BSA-PBS, and suspended in 
1%  BSA-PBS.  PC  and fl-phenyl-N-acetyl-D-glueosaminide  (NAG)  immunoabsorbents were 
prepared as described previously (27, 28). NMS were absorbed by adding 6 ×  l0  s bacteria or 
0.05  ml immunoabsorbent/ml of NMS and rotating at 4°C for 24-36 h.  The absorbed sera 
were clarified by centrifugation and then sterilized by filtration before use. 
Suppression of T-15 Idiotype.  The anti-PC response of mice was suppressed by administration 
of monoclonai anti-T-15 antibody derived from the hybridoma GB4-10-4.  Details on prepara- 
tion, characterization, and  suppressive characteristics  of this  monoclonal antibody will be 
described elsewhere.  Briefly, this hybridoma was derived from a fusion of HOPC-8-immunized 
A/J lymph node cells with the myeloma P3 NS1Ag4-1.  The anti-idiotype antibody is yl#¢, its 
binding to T-15 is inhibited by PC-keyhole limpet hemocyanin (KLH) but not by PC and it 
is specific for idiotypic determinants on T-15 and H8 but not two other PC-binding  myelomas, 
MOPCI67 and MOPC511. Adult mice were suppressed by four daily injections of 100/xg of 
purified antibody before challenge with pneumococeus. This dose has been shown to inhibit 
both the T-15 idiotype and total anti-PC response (Kearney, Barletta, Quan, and Quintans, 
manuscript in preparation). 
Protection with Hybridoma Antibodies.  IgM anti-type 3 hybridomas CA3-1, CC4-8, and DB6 
have been described previously (29). IgM anti-PC hybridoma M2 was obtained from Dr. P. 
Gearhart, Carnegie Institute of Technology. Anti-S. typhimurium hybridoma, ST-1, was obtained 
from P. Basta, University of Alabama in Birmingham. Hybridoma antibodies from all tumors 
except M2 were raised as ascites  in BALB/c mice. The M2 tumor was raised in C  ×  D male 
mice. 
The amount of antibody in these fluids was estimated by determining the total levels of IgM 
(30) in the ascites fluids. The concentrations of antibody in these ascites fluids ranged from 5- 
20 mg/ml. Mice were injected intraperitoneally 1 and 2 d later with 0.1 ml of diluted ascites 
fluid containing 200 gg of hybridoma antibody 2 h  before intravenous inoculation of pneu- 
mococci.  Control mice received 0.1 ml of a  1:50 dilution of BALB/cJ NMS. 
Results 
Susceptibility of xid Mice  to  Type 3  Pneumococci.  To examine  the  effects of the xid 
allele  on  the  susceptibility  of  mice  to  pneumococcal  infection,  we  infected  the 
reciprocal  Fa  males obtained by crossing DBA/2  and CBA/N  mice. Males derived 
from a  CBA/N  mother  (C  ×  D)  express the  recessive X-linked  immunodeficiency, 
whereas males with a  DBA/2  mother (D ×  C)  are normal in their immune respon- 
siveness (6,  12). 
When these mice were infected intravenously, we could easily distinguish between 
xid normal and defective mice (Table I). When the infections were given intraperito- 
neally, even the immunologically "normal" D  ×  C  males were highly susceptible, as 
expected  (31,  32).  We found that C  ×  D  males could be killed with  ~1,000-10,000 
times fewer type 3 S. pneumoniae pneumococci than D  ×  C  males or C  ×  D  females. 
TABLE I 
LDso of Pneumococci in xid Normal and Defective Mice 
Pneumococcal  Route of infection  strain 
Mice 
C×D~  C×  D~  D×Cd 
WU 1  Intravenous  104.  ND~  107 
WU2  Intravenous  101  105  105 
WU2  Intraperitoneal  < 101  101  102 
* LD~0. All deaths occurred between 1 and 5 d after infection. 
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Many of the C  X  D  males died within 2 d  (Fig.  1). It seemed unlikely that the early 
deaths of the C  ×  D males were the result of their inability to respond to the infection 
by the production of antibody, because even normal mice would not be expected to 
produce appreciable serum levels of antibody within the first 2 d (33, 34). One possible 
explanation  was that  C  ×  D  males lacked "naturally  occurring"  anticarbohydrate 
antibody cross-reactive with type 3 S. pneumoniae. 
Protection of xid Mice  with  NMS.  To  determine  whether  normal  mouse  sera  are 
protective, we incubated  the infecting doses of pneumococci at 0°C  with 0.2  ml of 
heat-inactivated NMS from either C  X D or D  x  C  male mice. This incubation step 
did not reduce the numbers of viable pneumococci, as determined by growth on blood 
plates.  Mice were injected intravenously with 0.2  ml of the incubation  mixture and 
injected  intraperitoneally  with  additional  0.2-ml vol  of the  corresponding  normal 
serum  at  1 and  2  d  after infection.  From  the  data  plotted  in  Fig.  2A  and  B,  it  is 
apparent  that  even these small amounts of D  ×  C  male serum can protect C  X  D 
males from infection with pneumococcal strains WU 1 and WU2.  No protection was 
seen with C  ×  D  male serum. 
Specificity of Protective Antipneumococcal Antibody in NMS.  To investigate the specificity 
of the protective antibody, we absorbed normal serum with formalin-killed bacteria. 
The results of this study are depicted  in  Fig.  3A, where it can seen that absorption 
with  either  the  encapsulated  strain,  WU2,  or  the  nonencapsulated  strain,  R36A, 
removed most of the protective ability from the serum. Absorption with strain J 17A4 
had a much smaller effect. Because strain R36A is a genetically nonencapsulated type 
2 pneumococcal strain,  these data indicate that the protective antibodies in normal 
serum are not  directed against  the type 3 capsule of the pneumococcus but against 
some other component(s). Because both the WU2 and R36A strains should have PC 
in  their cell walls  (3), we suspected  that  the protective antibody might  be directed 
against this determinant. As expected, pooled normal sera from C  ×  D male mice had 
much lower levels of anti-PC antibody than sera from C  ×  D  females or D  ×  C  males 
(Table II) (35). The anti-PC antibody in D  ×  C male sera was in fact largely removed 
by absorption with both of the pneumococcal strains. The significance of the residual 
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Fro.  1.  Susceptibility of D  X  C  and  C  X  D  males to  type 3  S. pneumoniae.  Mice were  infected 
intravenously  with either 105 WUI (A) or 200 WU2 (B) on day 0. Each group contained 10 or more 
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Fio.  2.  Protection of C  X  D  males with NMS. Mice were infected intravenously with either  105 
WUI  (A) or 200 WU2 (B) in 0.2 ml of heat-inactivated C  x  D male or D x  C  male NMS on day 
0.  The bacteria were incubated  with the NMS for 30  min at  0°C before infection.  Each  group 
contained  10 or more mice. 
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Fro.  3.  Protection of C  x  D  males with  absorbed D  X  C  male NMS.  Preliminary  experiments 
indicated that  1-20D U  (420 nm) of formalized strain WU2 S. pneumoniae were required to absorb 
out most of the protective activity of 1 ml ofD X C male serum. In these experiments, D ×  C serum 
was absorbed with 20D  U/ml (109) killed  bacteria  (A) or 0.05  ml of immunoabsorbent (B) per 
milliliter of NMS. Live WU2 bacteria were then incubated in the absorbed NMS before injection 
as in Fig.  2. Bacteria used for absorption were WU2, type 3 S. pneumoniae, R36A, nonencapsulated 
(rough) S. pneumoniae, and J 174A, group A streptococci. Immunoabsorbents  used PCoSepharose and 
fl-phenyl-N-acetyt-o-glucosaminide-Sepharose. Each group contains nine or more mice. Significant 
differences from "none" at <0.03 and <0.01  are indicated by * and **, respectively. 
anti-PC antibody is unclear. It may be due to low affinity antibody because it is not 
absorbed  out  by an  excess  of bacteria.  The  anti-PC  antibody  was  only  partially 
absorbed by group A  streptococci. This partial  absorption by group A  streptococci 
correlates with the fact that this strain also partially removed protection from D  ×  C 
male sera. 
To  determine  whether  the  protective  antibodies  in  normal  sera  were  directed 
against PC, we absorbed D ×  C male serum with a PC-containing immunoabsorbent. 
As a control, the sera were absorbed with an immunoabsorbent containing NAG, the BRILES ET  AL. 
TABL~  II 
Titers of Anti-PC Antibody in NMS 
Anti-PC 
Serum pool  titer* 
C x  D male  6 
C ×  D female  106 
D X C male  113 
C ×  D male 
C ×  D male 
D × C male 
D × C male 
Inhibitor$ 
0.1% PC  10 
0.1% Rhamnose  11 
0.1% PC  3 
0.1% Rhamnose  96 
Absorbent§ 
3.0 ×  109 WU2  26 
1.0 x  10  s WU2  25 
0.33 ×  109 WU2  29 
0.1 ×  109 WU2  61 
1.0 ×  109 R36A  25 
1,0 ×  10aJI7A4  72 
1.0 ×  109 Listeria  110 
PC-Sepharose  33 
NAG-Sepharose  107 
D × C male 
D × C male 
D × C male 
D × C male 
D × C male 
D × C male 
D × C male 
D × C male 
D × C male 
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* Dilution  of antisera  binding  50%  of labeled  anti-•  (see Materials  and 
Methods). Each value is an average of two or more determinations. By using 
anti-PC hybridoma M2 as a standard, the concentrations of anti-PC antibody 
in C  X D male, C  X D female,  and D X C male sera are 15, 258, and 265 
ng/ml. 
$ Normal mouse sera were titered out in the indicated inhibitors diluted in 1% 
BSA-PBS. 
§ Absorptions  were  done  as  described  in  Fig.  2.  Numbers  of bacteria  for 
absorption were determined from the OD 420 nm of washed  bacteria. 
immunodominant  group of streptococcal group A  carbohydrate.  The results shown in 
Figure 3B indicate that only the PC immunoabsorbent  removed the protective ability. 
Thus  it appears  likely that  anti-PC  antibodies  in normal sera play an important  role 
in the resistance of mice to pneumococcai  infection. 
Pneumococcal Susceptibility  of Mice  Whose  Anti-PC  Antibody  Response  Has  Been Sup- 
pressed.  Because  of the  unexpected  nature  of the  above  observations,  we sought  to 
determine by a  completely different method  whether anti-PC  antibodies were in fact 
essential  for protection  against  pneumococcal  infection.  Most  anti-PC  antibodies  in 
BALB/c  mice bear a  common  idiotype, T-15  (36,  37).  It has  been  shown  previously 
that, in the adult, passive administration of antibodies reactive with the T-15 idiotype 
can  suppress  the  production  of most  anti-PC  antibodies  (38,  39)  without  affecting 
responsiveness  to other antigens.  Thus,  we used  the anti-T-15  hybridoma,  GB4-10-4 
(71,x), to suppress  the anti-PC responses of BALB/c  mice. The dose of GB4-10-4 used 
has  been  shown  to  block  induced  anti-PC  responses  in  BALB/c  mice  (Kearney, 
Barletta, Quan,  and  Quintans,  manuscript  in preparation)  and  in this study reduced 
the  levels Of naturally  occurring  anti-PC  antibody  to  <1/3  of normal  levels. These 
mice were infected with 5  ×  103 WU2,  a  dose not normally fatal to BALB/c  mice. As 
can be seen in Fig. 4, most of the suppressed  mice and  none of the control mice died 
of pneumococcal  infection. 
Protection of xid Mice with Hybridoma Antibodies.  Finally, we examined  the ability of 700  ANTIPHOSPHOCHOLINE  ANTIBODIES  IN NORMAL MOUSE  SERUM 
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FIG.  4.  Effect of anti-PC suppression on the resistance of BALB/cJ  mice to S. #neumoniae. Anti-PC 
antibody production was suppressed by intraperitoneal injection of 100/~g/d of GB4-10-4 anti-T-15 
hybridoma. After a  week of daily injections, mice were rested 6  d, bled on day  7,  and infected 
intravenously on day 8 with 5 ×  l0  s WU2. Each group contained eight mice. 
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FIG. 5.  Protection of C  X D males with passive antibody. Mice were injected intraperitoneally 
with 0.1 ml of diluted hybridoma-containing  as,  cites fluid or 1:50 BALB/cJ NMS (none) 2 h before 
and 1 and 2 d after intravenous  injection of 200 (A) or 5,000 (B) viable WU2. In B, each group 
contained eight or more mice. In A, the numbers of mice per group were 7 anti-PC;  15 anti-SSS-III; 
4 anti-Salmonella;  and  7 NMS.  Significant  difference from  "none" at  P <0.03  or P <0.01  is 
indicated by * or **, respectively. 
IgM hybridoma antibodies to either type 3  polysaccharide, PC, or S.  typhimurium  to 
protect C  X  D  males from  pneumococcal infection.  Mice were injected intraperito- 
neally with 200/xg of hybridoma antibody in 0.1 ml of diluted aseitic fluid 2 h  before 
inoculation with either 200 or 5,000 colony-forming units of strain WU-2, S. pneumoniae 
(Fig. 5). To conti"ol for possible protection by naturally occurring antipneumoeoccal 
antibodies in the ascitic fluids, we injected a group of mice with a comparable dilution 
(1:50) of BALB/c NMS (Fig. 5). To further exclude the possibility that any protection 
obtained with the anti-PC hybridoma might be due to naturally occurring antibody, 
the M2-containing ascitic fluid was  obtained  from  C  X  D  male  mice carrying the 
tumor. 
The results of these experiments demonstrated  that  the anti-PC  hybridoma, M2, 
and  the  three  IgM  anti-type  3  hybridomas,  CA3-1,  CC4-8,  and  DB6,  all  gave 
protection. The three anti-type 3  hybridomas mediated similar levels of protection, 
and  their pooled data are depicted. Protection was  also observed with  isolated M2 
and CC4-8  (data not shown).  The anti-Salmonella hybridoma showed significantly 
less protection. Although we do not yet know the minimum  amounts of hybridoma BRILES  ET  AL.  701 
antibody required, it is now clear that as little as 20 #g/d of M2 and CA3-1 antibody 
can provide complete protection. 
Discussion 
In these studies we used immunodeficient xid mice to examine the importance of 
anticarbohydrate antibody in  the defense of mice against  pneumococcal infection. 
We expected C  ×  D  male mice to be highly susceptible to pneumococca! infection 
because they are unable to make antibodies to the capsule of the type 3 pneumococcus 
(5), and earlier reports had indicated that anticapsular antibodies were important for 
protection against pneumococcal infection (1, 31, 40). We were quite surprised when 
our results demonstrated that not only do antibodies in normal serum offer significant 
protection against  pneumococcal infection, but  these  normal  serum  antibodies are 
reactive with the PC determinant of the cell wall rather than with the capsule. 
We do not feel that our results negate any of the studies showing that anticapsular 
antibody is highly effective in the defense against  pneumococcal infection. On  the 
contrary,  the  role  of anti-PC  antibody  may  account  for some  of the  nonspecific 
immunity to pneumococci (41, 42) and may delay the infection until protective levels 
of anticapsular antibody are generated. 
If anti-PC antibodies do play an important role in the defense against pneumococci 
or  other  pathogens,  it  might  explain  in  part  why  anti-PC  antibodies  show  such 
extreme homogeneity of their specificity (43), idiotype (36, 44), and structure (45-47). 
The naturally occurring anti-PC antibodies we find in normal sera are probably 
the result of immunostimulation with PC-containing environmental antigens. PC has 
been found on the surface of many microbes, including a number of different bacteria, 
fungi, and nematodes (48, 49). Naturally occurring anti-PC antibodies are commonly 
found in sera of mouse strains (35) other than CBA/N and are easily demonstrable in 
normal  human  sera  (D.  E.  Briles and  C.  Forman,  unpublished  observations). The 
existence  of anti-C  carbohydrate  antibody  in  human  sera  has  been  established 
previously (50). 
There may be several reasons why protection with anti-PC antibody has not been 
reported before. Isolated C carbohydrate is poorly immunogenic (51), and even when 
an anti-PC response was induced, it may not have always raised the levels of anti-PC 
antibody sufficiently higher than  the naturally occurring levels to cause a  marked 
difference in  protection.  Furthermore, the  early and  dramatic  successes of raising 
type-specific protective antibody to isolated pneumococcal capsules (1, 40) probably 
reduced interest in studies of protective antibodies to pneumococcal antigens other 
than capsular polysaeeharides. 
Although we know of no previous reports indicating that anti-PC  antibodies are 
protective against  pneumococcal infection, the older literature does contain several 
reports  of immunizations  with  whole  bacteria  (52,  53)  or  bacterial  fractions  that 
yielded protection in rabbits across type barriers  (54-56).  The protection could be 
transferred with serum to other rabbits but not to mice (52). More recently, Thompson 
and Eisenstein (57) have shown that a vaccine composed of a subcellular preparation 
of rough type 3  pneumococci could protect mice from infection with encapsulated 
types  1, 2, or 3 pneumococci. It seems likely that at least some of these reports dealt 
with the effects of anti-PC antibody. 
One of the most compelling findings was that of Dubos (58), who reported that if 702  ANTIPHOSPHOCHOLINE ANTIBODIES  IN NORMAL MOUSE SERUM 
autolysates of rough or smooth pneumococci were injected into rabbits, antisera could 
be produced that could protect mice against pneumococci regardless of their capsular 
type. Neither the nature of the antigen that induced these antibodies nor the antibody 
specificity  was  reported.  However,  it  was  known  that  autolysates  of pneumococci 
contain C carbohydrate (59), and more recently it has been shown that PC is a major 
antigenic  determinant  of C  carbohydrate  (60).  Choline  has  also  been  shown  to  be 
present  in pneumococcal F antigen  (61). 
The  fact  that  anti-PC  antibodies  are  protective  against  encapsulated  type  3 
pneumococci  is  particularly  interesting  because  all  strains  of S.  pneumoniae  have  C 
carbohydrate in their cell walls  (3,  51). 
Summary 
The  antiphosphocholine  (PC)  antibody in  normal  mouse  sera  (NMS)  provides 
protection  against  intravenous  infection  with  encapsulated  strain  WU2  of type  3 
Streptococcus pneumoniae.  Mice unable to mak~ anti-PC antibody, as a result of suppres- 
sion with anti-T-15 idiotype or inheritance of the xid gene of CBA/N mice, are highly 
susceptible to infection with strain WU2. Mice inheriting the xid gene can be protected 
with  NMS  from  immunologically  normal  mice  or  with  IgM  hybridoma  anti-PC 
antibody. The protective effect of NMS can be removed with PC-containing immu- 
noabsorbents. 
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